The CAS Decision reveals that Salazar was prescribed testosterone in 1991 after being diagnosed with testicular failure, later (from 2005) being prescribed with AndroGel
Pricing Pressure Accelerates Adoption At $149/month self-pay for the starter dose, oral GLP-1s enter the market at a materially more accessible price point than injectable WEGOVY (which retails at $1,349/month before discounts)
The standard regimen involves: Loading doses without neurological involvement : 1 mg intramuscularly three times a week for 2 weeks [3] [8] Loading doses with neurological involvement : 1 mg intramuscularly on alternate days until no further improvement [3] [8] Maintenance therapy : 1 mg every 23 months for life in cases of pernicious anaemia or irreversible malabsorption (every 2 months if neurological involvement) [3] [8] This aggressive approach aims to prevent irreversible neurological damage, though recovery of established neuropathy may be incomplete, particularly if treatment is delayed
Additional risk factors commonly present in patients prescribed GLP-1 receptor agonists include: Reduced physical activity and prolonged immobility Hypertension and other cardiovascular comorbidities Dyslipidaemia contributing to atherosclerosis Advanced age , as thrombotic risk increases with ageing Other important VTE risk factors include: Previous VTE or family history of clotting disorders Thrombophilia (inherited or acquired clotting disorders) Active cancer or cancer treatment Oestrogen-containing medications (HRT, combined oral contraceptives) Pregnancy and postpartum period Recent surgery, trauma or hospitalisation Long-haul travel with prolonged immobility Smoking When patients taking GLP-1 receptor agonists experience thrombotic events, it is important to consider these pre-existing risk factors as they often contribute significantly to clotting risk in this population
and lactatate dehydrogenase, LDH) were measured using an auto-analyzer AU-800 (Olympus, Tokyo), and troponin T was assessed by a rapid quantitative assay using the Cardiac Reader (Roche Diagnostics, Mannheim, Germany)
